FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979431718> ?p ?o ?g. }

• W2979431718 endingPage "S646" @default.
• W2979431718 startingPage "S645" @default.
• W2979431718 abstract "INTRODUCTION: Functional constipation (FC), also known as chronic idiopathic constipation, is a common problem in children that may severely impact quality of life and persist into adulthood. Currently there are no approved therapies for children and more effective treatments are needed to provide symptomatic relief. This study evaluated the safety and efficacy of a range of linaclotide (LIN) doses for treatment of FC in children aged 6–17 years. METHODS: This multicenter, randomized, double-blind, placebo (PBO)-controlled, parallel-group safety and efficacy study of a range of LIN doses compared to PBO randomized participants aged 6–11 years to once-daily PBO or LIN doses A, B, or C based on weight and those aged 12–17 years to once-daily PBO or LIN doses A, B, C, or 145 μg (Table 1) for 4 weeks. Primary efficacy endpoint was change from baseline (CFB) in 4-week overall spontaneous bowel movement (SBM) frequency rate. Secondary efficacy endpoints included CFB in 4-week daytime abdominal pain and bloating, stool consistency, straining severity, overall complete SBMs frequency rate, and daytime fecal incontinence. Safety assessments included adverse events (AEs), specifically AEs of special interest, treatment-emergent AEs (TEAEs), causality, severity, and serious AEs (SAEs). RESULTS: 173 participants were randomized; 90 (52%) aged 6–11 years and 83 (48%) aged 12–17 years. For the primary endpoint, or the secondary efficacy endpoints, none of the LIN doses (A, B, C) led to a clear improvement over PBO ( P ≥ 0.1502) in the ITT population. A trend toward improved efficacy at the high LIN dose vs. PBO was observed for the primary endpoint, stool consistency, and straining severity (Table 2). Similar results were observed in each age group. TEAEs were reported in 16.7% (LIN A), 29.3% (LIN B), 38.5% (LIN C), 22.0% (PBO), and 25% in the LIN 145 μg group (Table 3). The most commonly reported TEAE was diarrhea; the majority of cases were mild, and none were severe. No SAEs or AEs leading to discontinuation were reported in participants aged 6–11 years. Two SAEs were reported in participants aged 12–17 years (suicidal ideation and vomiting; 1 each); neither were considered related to study treatment. CONCLUSION: In children with FC, no clear improvement over PBO was observed for LIN; however, a trend for improved efficacy was observed at higher doses. LIN was well tolerated with a safety profile consistent with studies in adults with chronic idiopathic constipation." @default.
• W2979431718 created "2019-10-18" @default.
• W2979431718 creator A5006726610 @default.
• W2979431718 creator A5007914172 @default.
• W2979431718 creator A5036166472 @default.
• W2979431718 creator A5038294897 @default.
• W2979431718 creator A5044046992 @default.
• W2979431718 creator A5062274159 @default.
• W2979431718 creator A5068697150 @default.
• W2979431718 creator A5070564047 @default.
• W2979431718 creator A5079798362 @default.
• W2979431718 date "2019-10-01" @default.
• W2979431718 modified "2023-09-23" @default.
• W2979431718 title "1151 Linaclotide Safety and Efficacy in Children Aged 6 to 17 Years With Functional Constipation" @default.
• W2979431718 doi "https://doi.org/10.14309/01.ajg.0000594132.11221.16" @default.
• W2979431718 hasPublicationYear "2019" @default.
• W2979431718 type Work @default.
• W2979431718 sameAs 2979431718 @default.
• W2979431718 citedByCount "5" @default.
• W2979431718 countsByYear W29794317182021 @default.
• W2979431718 countsByYear W29794317182023 @default.
• W2979431718 crossrefType "journal-article" @default.
• W2979431718 hasAuthorship W2979431718A5006726610 @default.
• W2979431718 hasAuthorship W2979431718A5007914172 @default.
• W2979431718 hasAuthorship W2979431718A5036166472 @default.
• W2979431718 hasAuthorship W2979431718A5038294897 @default.
• W2979431718 hasAuthorship W2979431718A5044046992 @default.
• W2979431718 hasAuthorship W2979431718A5062274159 @default.
• W2979431718 hasAuthorship W2979431718A5068697150 @default.
• W2979431718 hasAuthorship W2979431718A5070564047 @default.
• W2979431718 hasAuthorship W2979431718A5079798362 @default.
• W2979431718 hasConcept C126322002 @default.
• W2979431718 hasConcept C142724271 @default.
• W2979431718 hasConcept C159110408 @default.
• W2979431718 hasConcept C168563851 @default.
• W2979431718 hasConcept C197934379 @default.
• W2979431718 hasConcept C203092338 @default.
• W2979431718 hasConcept C204787440 @default.
• W2979431718 hasConcept C27081682 @default.
• W2979431718 hasConcept C2776956441 @default.
• W2979431718 hasConcept C2777054765 @default.
• W2979431718 hasConcept C2779951463 @default.
• W2979431718 hasConcept C2780580376 @default.
• W2979431718 hasConcept C2780955771 @default.
• W2979431718 hasConcept C2781112942 @default.
• W2979431718 hasConcept C2908647359 @default.
• W2979431718 hasConcept C71924100 @default.
• W2979431718 hasConcept C99454951 @default.
• W2979431718 hasConceptScore W2979431718C126322002 @default.
• W2979431718 hasConceptScore W2979431718C142724271 @default.
• W2979431718 hasConceptScore W2979431718C159110408 @default.
• W2979431718 hasConceptScore W2979431718C168563851 @default.
• W2979431718 hasConceptScore W2979431718C197934379 @default.
• W2979431718 hasConceptScore W2979431718C203092338 @default.
• W2979431718 hasConceptScore W2979431718C204787440 @default.
• W2979431718 hasConceptScore W2979431718C27081682 @default.
• W2979431718 hasConceptScore W2979431718C2776956441 @default.
• W2979431718 hasConceptScore W2979431718C2777054765 @default.
• W2979431718 hasConceptScore W2979431718C2779951463 @default.
• W2979431718 hasConceptScore W2979431718C2780580376 @default.
• W2979431718 hasConceptScore W2979431718C2780955771 @default.
• W2979431718 hasConceptScore W2979431718C2781112942 @default.
• W2979431718 hasConceptScore W2979431718C2908647359 @default.
• W2979431718 hasConceptScore W2979431718C71924100 @default.
• W2979431718 hasConceptScore W2979431718C99454951 @default.
• W2979431718 hasIssue "1" @default.
• W2979431718 hasLocation W29794317181 @default.
• W2979431718 hasOpenAccess W2979431718 @default.
• W2979431718 hasPrimaryLocation W29794317181 @default.
• W2979431718 hasRelatedWork W130434534 @default.
• W2979431718 hasRelatedWork W1544394016 @default.
• W2979431718 hasRelatedWork W2027370521 @default.
• W2979431718 hasRelatedWork W2766008196 @default.
• W2979431718 hasRelatedWork W2979610633 @default.
• W2979431718 hasRelatedWork W3135320265 @default.
• W2979431718 hasRelatedWork W3172359983 @default.
• W2979431718 hasRelatedWork W4243345359 @default.
• W2979431718 hasRelatedWork W4292647012 @default.
• W2979431718 hasRelatedWork W4386127932 @default.
• W2979431718 hasVolume "114" @default.
• W2979431718 isParatext "false" @default.
• W2979431718 isRetracted "false" @default.
• W2979431718 magId "2979431718" @default.
• W2979431718 workType "article" @default.